← Back to home

NLRC4-GOF, AIFEC (AUTOINFLAMMATION WITH INFANTILE ENTEROCOLITIS), XIAP DEFICIENCY, CDC42 MUTATIONS

Clinical trials for NLRC4-GOF, AIFEC (AUTOINFLAMMATION WITH INFANTILE ENTEROCOLITIS), XIAP DEFICIENCY, CDC42 MUTATIONS explained in plain language.

Never miss a new study

Get alerted when new NLRC4-GOF, AIFEC (AUTOINFLAMMATION WITH INFANTILE ENTEROCOLITIS), XIAP DEFICIENCY, CDC42 MUTATIONS trials appear

Sign up with your email to follow new studies for NLRC4-GOF, AIFEC (AUTOINFLAMMATION WITH INFANTILE ENTEROCOLITIS), XIAP DEFICIENCY, CDC42 MUTATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Experimental drug aims to tame rare, devastating immune flares

Disease control Ongoing

This study is testing an investigational drug called MAS825 to see if it can prevent painful disease flares in people with rare, genetic immune conditions like NLRC4-GOF, XIAP deficiency, or CDC42 mutations. About 17 patients will receive the drug, and some will later be randomly…

Matched conditions: NLRC4-GOF, AIFEC (AUTOINFLAMMATION WITH INFANTILE ENTEROCOLITIS), XIAP DEFICIENCY, CDC42 MUTATIONS

Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Apr 04, 2026 00:50 UTC

NLRC4-GOF, AIFEC (AUTOINFLAMMATION WITH INFANTILE ENTEROCOLITIS), XIAP DEFICIENCY, CDC42 MUTATIONS

Get alerted when new NLRC4-GOF, AIFEC (AUTOINFLAMMATION WITH INFANTILE ENTEROCOLITIS), XIAP DEFICIENCY, CDC42 MUTATIONS trials appear

Experimental drug aims to tame rare, devastating immune flares